Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,525 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Tenofovir alafenamide for hepatitis B virus infection including switching therapy from tenofovir disoproxil fumarate.
Kaneko S, Kurosaki M, Tamaki N, Itakura J, Hayashi T, Kirino S, Osawa L, Watakabe K, Okada M, Wang W, Shimizu T, Higuchi M, Takaura K, Yasui Y, Tsuchiya K, Nakanishi H, Takahashi Y, Watanabe M, Izumi N. Kaneko S, et al. J Gastroenterol Hepatol. 2019 Nov;34(11):2004-2010. doi: 10.1111/jgh.14686. Epub 2019 May 21. J Gastroenterol Hepatol. 2019. PMID: 31017689
Efficacy of additional radiofrequency ablation after transcatheter arterial chemoembolization for intermediate hepatocellular carcinoma.
Azuma S, Asahina Y, Nishimura-Sakurai Y, Kakinuma S, Kaneko S, Nagata H, Goto F, Ootani S, Kawai-Kitahata F, Taniguchi M, Murakawa M, Watanabe T, Tasaka-Fujita M, Itsui Y, Nakagawa M, Watanabe M. Azuma S, et al. Among authors: kaneko s. Hepatol Res. 2016 Apr;46(4):312-9. doi: 10.1111/hepr.12566. Epub 2015 Sep 15. Hepatol Res. 2016. PMID: 26224167
Comprehensive analyses of mutations and hepatitis B virus integration in hepatocellular carcinoma with clinicopathological features.
Kawai-Kitahata F, Asahina Y, Tanaka S, Kakinuma S, Murakawa M, Nitta S, Watanabe T, Otani S, Taniguchi M, Goto F, Nagata H, Kaneko S, Tasaka-Fujita M, Nishimura-Sakurai Y, Azuma S, Itsui Y, Nakagawa M, Tanabe M, Takano S, Fukasawa M, Sakamoto M, Maekawa S, Enomoto N, Watanabe M. Kawai-Kitahata F, et al. Among authors: kaneko s. J Gastroenterol. 2016 May;51(5):473-86. doi: 10.1007/s00535-015-1126-4. Epub 2015 Nov 9. J Gastroenterol. 2016. PMID: 26553052
Evaluation of Interferon Resistance in Newly Established Genotype 1b Hepatitis C Virus Cell Culture System.
Taniguchi M, Tasaka-Fujita M, Nakagawa M, Watanabe T, Kawai-Kitahata F, Otani S, Goto F, Nagata H, Kaneko S, Nitta S, Murakawa M, Nishimura-Sakurai Y, Azuma S, Itsui Y, Mori K, Yagi S, Kakinuma S, Asahina Y, Watanabe M. Taniguchi M, et al. Among authors: kaneko s. J Clin Transl Hepatol. 2016 Mar 28;4(1):5-11. doi: 10.14218/JCTH.2015.00047. Epub 2016 Mar 15. J Clin Transl Hepatol. 2016. PMID: 27047766 Free PMC article.
Serial measurement of Wisteria floribunda agglutinin positive Mac-2-binding protein is useful for predicting liver fibrosis and the development of hepatocellular carcinoma in chronic hepatitis C patients treated with IFN-based and IFN-free therapy.
Nagata H, Nakagawa M, Nishimura-Sakurai Y, Asano Y, Tsunoda T, Miyoshi M, Kaneko S, Goto F, Otani S, Kawai-Kitahata F, Murakawa M, Nitta S, Itsui Y, Azuma S, Kakinuma S, Tojo N, Tohda S, Asahina Y, Watanabe M; Ochanomizu Liver Conference Study Group. Nagata H, et al. Among authors: kaneko s. Hepatol Int. 2016 Nov;10(6):956-964. doi: 10.1007/s12072-016-9754-1. Epub 2016 Jul 19. Hepatol Int. 2016. PMID: 27435935
Hepatic IFNL4 expression is associated with non-response to interferon-based therapy through the regulation of basal interferon-stimulated gene expression in chronic hepatitis C patients.
Murakawa M, Asahina Y, Kawai-Kitahata F, Nakagawa M, Nitta S, Otani S, Nagata H, Kaneko S, Asano Y, Tsunoda T, Miyoshi M, Itsui Y, Azuma S, Kakinuma S, Tanaka Y, Iijima S, Tsuchiya K, Izumi N, Tohda S, Watanabe M. Murakawa M, et al. Among authors: kaneko s. J Med Virol. 2017 Jul;89(7):1241-1247. doi: 10.1002/jmv.24763. Epub 2017 Feb 27. J Med Virol. 2017. PMID: 28036111
ITPA gene variation and ribavirin-induced anemia in patients with genotype 2 chronic hepatitis C treated with sofosbuvir plus ribavirin.
Murakawa M, Asahina Y, Nagata H, Nakagawa M, Kakinuma S, Nitta S, Kawai-Kitahata F, Otani S, Kaneko S, Miyoshi M, Tsunoda T, Asano Y, Sato A, Itsui Y, Azuma S, Nouchi T, Furumoto Y, Asano T, Chuganji Y, Tohda S, Watanabe M. Murakawa M, et al. Among authors: kaneko s. Hepatol Res. 2017 Oct;47(11):1212-1218. doi: 10.1111/hepr.12867. Epub 2017 Mar 7. Hepatol Res. 2017. PMID: 28128521
Effect of interferon-based and -free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C.
Nagata H, Nakagawa M, Asahina Y, Sato A, Asano Y, Tsunoda T, Miyoshi M, Kaneko S, Otani S, Kawai-Kitahata F, Murakawa M, Nitta S, Itsui Y, Azuma S, Kakinuma S, Nouchi T, Sakai H, Tomita M, Watanabe M; Ochanomizu Liver Conference Study Group. Nagata H, et al. Among authors: kaneko s. J Hepatol. 2017 Nov;67(5):933-939. doi: 10.1016/j.jhep.2017.05.028. Epub 2017 Jun 14. J Hepatol. 2017. PMID: 28627363
Prediction of Hepatocellular Carcinoma After Sustained Virological Responses Using Magnetic Resonance Elastography.
Higuchi M, Tamaki N, Kurosaki M, Watakabe K, Osawa L, Wang W, Okada M, Shimizu T, Takaura K, Takada H, Kaneko S, Yasui Y, Tsuchiya K, Nakanishi H, Itakura J, Takahashi Y, Izumi N. Higuchi M, et al. Among authors: kaneko s. Clin Gastroenterol Hepatol. 2019 Nov;17(12):2616-2618. doi: 10.1016/j.cgh.2018.11.046. Epub 2018 Nov 28. Clin Gastroenterol Hepatol. 2019. PMID: 30502507
3,525 results